This inventor holds 2 USPTO granted patents and 2 published patent applications, plus 1 CIPO patent and 3 EPO patents. Top assignees: Ludwig-Maximilians-Universitat München, Max-Planck-Gesellschaft Zur Förderung Der Wissenschaften E. V. . Active years: 2018-2019.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
2 out of 50 
2 out of 1,334 
Years Active: 2018-2019
Title: Hans Kretzschmar: Innovator in Neurodegenerative Disease Research
Introduction
Hans Kretzschmar is a notable inventor based in Hohenschäftlarn, Germany. He has made significant contributions to the field of neurodegenerative diseases, holding 2 patents that focus on innovative drug formulations. His work aims to address critical health challenges associated with protein aggregation.
Latest Patents
Kretzschmar's latest patents include a drug designed to inhibit the aggregation of proteins involved in diseases linked to protein aggregation and neurodegenerative conditions. The invention relates to a compound represented by a specific formula for use in the treatment or prevention of these diseases. Additionally, it encompasses pharmaceutical and diagnostic compositions that include the compound, as well as a kit for preparing a detectably labeled version of the compound. Furthermore, the invention outlines a method for imaging deposits of aggregated proteins.
Career Highlights
Throughout his career, Kretzschmar has been associated with prestigious institutions such as the Max Planck Society for the Advancement of Science and Ludwig Maximilian University of Munich. His work in these organizations has allowed him to advance his research and contribute to the scientific community.
Collaborations
Some of Kretzschmar's notable coworkers include Armin Giese and Uwe Bertsch. Their collaborative efforts have further enriched the research landscape in the field of neurodegenerative diseases.
Conclusion
Hans Kretzschmar's innovative work in developing drugs for neurodegenerative diseases highlights his commitment to addressing significant health issues. His contributions through patents and collaborations continue to impact the scientific community positively.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile